DNTH Stock Analysis: Dianthus Therapeutics | NASDAQ
Biotechnology | NASDAQ, USA | Market Cap: 5.329m USD | 12M Return: 424.7% | Charts, Fundamentals & Technical Analysis
Avg Turnover: 111M
Warnings
Tailwinds
Seasonality 8 years of data
How good or bad each month usually is (without trend). The score below shows how much you can trust it: 0 = pure chance, >40 gets interesting and >55 is strong.
Dianthus Therapeutics, Inc. (NASDAQ: DNTH) is a clinical-stage biotechnology company developing therapies for patients with severe autoimmune diseases. Its lead candidate, claseprubart, is an engineered monoclonal antibody designed for extended half-life, improved potency, and selective targeting of the active C1s complement protein. The company is also developing DNTH212, a bifunctional fusion protein that targets plasmacytoid dendritic cell BDCA2 to reduce Type 1 interferon production while simultaneously inhibiting BAFF/APRIL to suppress B cell function. Founded in 2019, Dianthus is headquartered in New York, New York, and went public in September 2023.
As a clinical-stage biotechnology company, Dianthus does not yet market approved products and its value is tied to the progression of its drug pipeline through clinical trials and potential regulatory approval, with future revenue dependent on commercialization or partnership deals typical of the biopharmaceutical sector.
- Claseprubart Phase 3 CIDP data readout as key pipeline catalyst
- Complement competitor approvals pressure claseprubart market entry timing
- Cash runway extension via follow-on offering funds pivotal trials
| Net Income: -11.3m TTM > 0 and > 6% of Revenue |
| FCF/TA: -0.10 > 0.02 and ΔFCF/TA 15.63 > 1.0 |
| NWC/Revenue: 81.0k% < 20% (prev 3.89k%; Δ 77.1k% < -1%) |
| CFO/TA -0.10 > 3% & CFO -130.3m > Net Income -11.3m |
| Net Debt/EBITDA: error (EBITDA <= 0) |
| Current Ratio: 29.25 > 1.5 & < 3 |
| Outstanding Shares: last quarter (48.0m) vs 12m ago 34.20% < -2% |
| Gross Margin: 94.31% > 18% (prev 93.29%; Δ 1.03% > 0.5%) |
| Asset Turnover: 0.17% > 50% (prev 1.87%; Δ -1.70% > 0%) |
| Interest Coverage Ratio: error (cannot be calculated; needs correct EBIT TTM and Interest Expense TTM) |
| A: 0.87 (Total Current Assets 1.12b - Total Current Liabilities 38.3m) / Total Assets 1.25b |
| B: -0.30 (Retained Earnings -377.6m / Total Assets 1.25b) |
| C: -0.01 (EBIT TTM -11.3m / Avg Total Assets 797.7m) |
| D: 26.36 (Book Value of Equity 1.20b / Total Liabilities 45.6m) |
| Altman-Z'' = 32.29 = AAA |
| DSRI: 3.0 (Receivables 1.23m/1.00m, Revenue 1.34m/6.52m) |
| GMI: 0.99 (GM 93.29% / 94.31%) |
| AQI: 0.46 (AQ_t 0.10 / AQ_t-1 0.22) |
| SGI: 0.20 (Revenue 1.34m / 6.52m) |
| TATA: 0.10 (NI -11.3m - CFO -130.3m) / TA 1.25b) |
| Beneish M = -2.27 (Cap -4..+1) = BBB |
As of July 08, 2026, the stock is trading at USD 95.76 with a total of 819,540 shares traded. Over the past week, the price has changed by +0.08%, over one month by +17.90%, over three months by +11.09% and over the past year by +424.71%.
Current recommended Stop Loss: 88.80 (which is 7.3% or 1.2 ATR below the current price).
Dianthus Therapeutics has received a consensus analysts rating of 4.83. Therefore, it is recommended to buy DNTH.
- StrongBuy: 10
- Buy: 2
- Hold: 0
- Sell: 0
- StrongSell: 0
| Analysts Target Price | 127.7 | 33.3% |
P/S = 3988.671
P/B = 4.434
Revenue TTM = 1.34m USD
EBIT TTM = -11.3m USD
EBITDA TTM = -10.9m USD
Long Term Debt = 965k USD (estimated: total debt 1.36m - short term 399k)
Short Term Debt = 399k USD (from shortTermDebt, last quarter)
Debt = 1.36m USD (from shortLongTermDebtTotal, last quarter) (leases 1.36m already included)
Net Debt = -1.11b USD (calculated: Debt 1.36m - CCE 1.11b)
Enterprise Value = 4.22b USD (5.33b + Debt 1.36m - CCE 1.11b)
Interest Coverage Ratio = unknown (Ebit TTM -11.3m / Interest Expense TTM 0.0)
EV/FCF = -32.33x (Enterprise Value 4.22b / FCF TTM -130.5m)
FCF Yield = -3.09% (FCF TTM -130.5m / Enterprise Value 4.22b)
FCF Margin = -9.77k% (FCF TTM -130.5m / Revenue TTM 1.34m)
Net Margin = -847.5% (Net Income TTM -11.3m / Revenue TTM 1.34m)
Gross Margin = 94.31% ((Revenue TTM 1.34m - Cost of Revenue TTM 76.0k) / Revenue TTM)
Gross Margin QoQ = 83.59% (prev none%)
Tobins Q-Ratio = 3.38 (Enterprise Value 4.22b / Total Assets 1.25b)
Interest Expense / Debt = 0.0% (Interest Expense 0.0 / Debt 1.36m)
Taxrate = 21.0% (US federal default 21%)
NOPAT = -8.95m (EBIT -11.3m * (1 - 21.00%)) [loss with tax shield]
Current Ratio = 29.25 (Total Current Assets 1.12b / Total Current Liabilities 38.3m)
Debt / Equity = 0.00 (Debt 1.36m / totalStockholderEquity, last quarter 1.20b)
Debt / EBITDA = 102.2 (negative EBITDA) (Net Debt -1.11b / EBITDA -10.9m)
Debt / FCF = 8.51 (negative FCF - burning cash) (Net Debt -1.11b / FCF TTM -130.5m)
Total Stockholder Equity = 636.1m (last 4 quarters mean from totalStockholderEquity)
RoA = -1.42% (Net Income -11.3m / Total Assets 1.25b)
RoE = -1.78% (Net Income TTM -11.3m / Total Stockholder Equity 636.1m)
RoCE = -1.78% (EBIT -11.3m / Capital Employed (Equity 636.1m + L.T.Debt 965k))
RoIC = -0.74% (negative operating profit) (NOPAT -8.95m / Invested Capital 1.21b)
WACC = 9.69% (E(5.33b)/V(5.33b) * Re(9.69%) + D(1.36m)/V(5.33b) * Rd(0.0%) * (1-Tc(0.21)))
Discount Rate = 9.69% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: 98.88 | Cagr: 185.6%
[DCF] Fair Price = unknown (Cash Flow -130.5m)
EPS Correlation: N/A | EPS CAGR: N/A | SUE: 1.92 | # QB: 1
Revenue Correlation: -33.69 | Revenue CAGR: -15.80% | SUE: 0.13 | # QB: 0
EPS current Quarter (2026-06-30): EPS=-0.91 | Chg30d=+0.00% | Revisions=+25% | Analysts=8
EPS next Quarter (2026-09-30): EPS=-1.02 | Chg30d=+0.00% | Revisions=+25% | Analysts=8
EPS current Year (2026-12-31): EPS=-3.93 | Chg30d=-0.71% | Revisions=+44% | GrowthEPS=+6.5% | GrowthRev=-40.6%
EPS next Year (2027-12-31): EPS=-4.65 | Chg30d=-0.50% | Revisions=+44% | GrowthEPS=-18.4% | GrowthRev=+31.1%
[Analyst] Revisions Ratio: +59% (up=12, down=2)